exercise and glp 1 Staying Strong While Using a GLP‑1 Medication: Why Matters Introducing GLP-1 Fitness Formula: For

Likewise, people with diabetes have a 40% greater risk of developing Parkinsons compared to people who do not have diabetes

When tested as a once-daily injection in single and multiple doses varying up to 0.18 mg in healthy normal to overweight volunteers, gastrointestinal adverse events (nausea, diarrhoea, constipation, vomiting) were encountered, but the drug was described as well tolerated

The data show that individuals who took GLP-1 agonists for a long duration had a lower risk of going on to develop more severe forms of liver disease, including cirrhosis and liver cancer

It found that GLP-1 use was associated with a significantly reduced long-term risk of TKA, and effects were greater with longer treatment duration and newer generation GLP-1s

But what will a small jab do to you

Phase 2 trial results (48 weeks, adults with obesity): 1 mg dose: 7.2% body weight loss 4 mg dose: 12.9% body weight loss 8 mg dose: 17.3% body weight loss 12 mg dose: 24.2% body weight loss Placebo: 1.6% body weight loss Phase 3 TRIUMPH-4 results: 9 mg dose: 20.0% body weight loss (22.9 kg / 50.5 lbs) 12 mg dose: 23.7% body weight loss (27.2 kg / 60.0 lbs) Placebo: 4.6% body weight loss In a separate phase 3 analysis, retatrutide at the highest dose achieved up to 28.7% weight loss